Small molecule · Inhibitor of dipeptidyl peptidase 1 (CTSC) · developed by Insmed
Brensocatib is an orally bioavailable, small molecule that competitively and reversibly inhibits dipeptidyl peptidase 1 (DPP1), reducing activation of neutrophil serine proteases such as neutrophil elastase during neutrophil maturation. It is studied in non-cystic fibrosis bronchiectasis and COVID-19.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Mar 16, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04594369 | Phase 3 | Non-Cystic Fibrosis Bronchiectasis | Completed | INSM |
| NCT04817332 | Phase 3 | Covid19 | Completed | INSM |
| NCT06344728 | Phase 1 | Healthy Participants | Completed | INSM |
| NCT05652257 | Phase 1 | Healthy Volunteers | Completed | INSM |
| NCT05927597 | Phase 1 | Healthy Volunteers | Completed | INSM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Covid19Healthy ParticipantsHealthy VolunteersNon-Cystic Fibrosis Bronchiectasis
Updated Oct 18, 2026. Something wrong or missing? Report it on the INSM page.
See INSM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
INSM catalysts and pipeline →